ArticleEndoscopic ultrasound
Prediction of pancreatic neuroendocrine tumor grading using an artificial intelligence-based video analysis model (GradAINet) applied to contrast-enhanced EUS videos.
Article in Endoscopic ultrasound. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Pancreatic neuroendocrine neoplasms (PNENs) are rare tumors with heterogeneous outcomes. Tumor grading (G), based on mitotic count and Ki-67 index, is the main prognostic factor guiding treatment. EUS-guided fine-needle aspiration/biopsy is the current standard but shows a misgrading rate up to 25%. We evaluated an artificial intelligence-based video analysis model to predict PNEN grading from contrast-enhanced EUS (CE-EUS) recordings. Methods: This retrospective study was conducted at Istituti di Ricovero e Cura a Carattere Scientifico San Raffaele Hospital, Milan, a European Neuroendocrine Tumor Society Center of Excellence. Patients were eligible if CE-EUS videos ≥1 minute (arterial and venous phases) and cyto-histological confirmation of PNEN were available. Exclusion criteria included mixed neuroendocrine-non-neuroendocrine neoplasms, missing Ki-67 grading, or poor video quality. CE-EUS videos were processed with a deep-learning video transformer model (GradAINet). The dataset was split into training (70%), validation (10%), and testing (20%) cohorts. Diagnostic performance was evaluated using sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and F1-score. Results: Between 2022 and 2024, 115 patients were included (49 female, 42.6%): 70 had G1, and 45 had G2-G3 tumors. Overall, 253,751 video frames were analyzed. GradAINet achieved a sensitivity of 0.817 (95% confidence interval [CI]: 0.556-1.000), specificity 0.806 (95% CI: 0.588-1.000), positive predictive value 0.759 (95% CI: 0.500-1.000), negative predictive value 0.856 (95% CI: 0.667-1.000), and accuracy 0.811 (95% CI: 0.654-0.962). Conclusion: This artificial intelligence-driven CE-EUS video model shows high accuracy for PNEN grading and potentially complements EUS-guided fine-needle aspiration/biopsy. As the first video-based rather than static-image model, it represents a methodological advance. Multicenter validation on larger cohorts is needed before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.